title: Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: a review of the literature.
abstract: OBJECTIVE
  To review the literature regarding the development of hyperglycemia associated with neoadjuvant agents used in the treatment of solid tumor cancers.
  
  
  METHODS
  Research articles were obtained from PubMed, CINAHL®, and Cochrane Reviews. The following search terms were used alone and in combination: diabetes, glycemic control, chemotherapy, androgen deprivation therapy, interferon-alpha, immunosuppressants, cancer, neoplasms, and hyperglycemia.
  
  
  RESULTS
  Twenty-two studies were identified reporting the development of hyperglycemic events in patients who received a variety of chemotherapeutic agents.
  
  
  CONCLUSIONS
  Findings suggest patients are at risk for the development of hyperglycemia from certain chemotherapeutic agents. Docetaxel, everolimus, and temsirolimus alone or in combination with other agents can promote hyperglycemia. Androgen-deprivation therapy commonly used in prostate cancer, increases the risk for the development of hyperglycemia and diabetes.
  
  
  CONCLUSIONS
  Oncology nurses play an important role in the identification and treatment of hyperglycemia in patients receiving chemotherapy. Future research is needed that focuses on the association between glycemic control and adverse outcomes in patients with a solid tumor cancer who are at risk for treatment-induced hyperglycemia.
authors.affiliation: College of Nursing, Michigan State University in East Lansing.
authors.forename: Denise Soltow
authors.initials: DS
authors.lastname: Hershey
authors.affiliation: School of Nursing, University of North Carolina-Chapel Hill.
authors.forename: Ashley Leak
authors.initials: AL
authors.lastname: Bryant
authors.affiliation: City of Hope National Medical Center, Duarte, CA.
authors.forename: Jill
authors.initials: J
authors.lastname: Olausson
authors.affiliation: Duke University Health System, Durham, NC.
authors.forename: Ellen D
authors.initials: ED
authors.lastname: Davis
authors.affiliation: University of Texas MD Anderson Cancer Center in Houston.
authors.forename: Veronica J
authors.initials: VJ
authors.lastname: Brady
authors.affiliation: College of Nursing, New York University in New York City.
authors.forename: Marilyn
authors.initials: M
authors.lastname: Hammer
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D020360:Neoadjuvant Therapy; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: chemotherapy; hyperglycemia; neoplasm